Verastem (VSTM) Receives Daily Media Sentiment Rating of 0.10
Media coverage about Verastem (NASDAQ:VSTM) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Verastem earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.6209422479994 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news headlines that may have impacted Accern’s scoring:
- Verastem Inc (VSTM) Expected to Announce Earnings of -$0.43 Per Share (americanbankingnews.com)
- Reviewing Verastem (VSTM) and Its Rivals (americanbankingnews.com)
- Verastem, Inc. (NASDAQ:VSTM) – Hot Mover of the Day – Nasdaq Journal (press release) (nasdaqjournal.com)
- Verastem, Inc. (VSTM) Making Active Thrust in Street with Future FinTech Group Inc. (FTFT) – Investing News Update (investingbizz.com)
- Verastem, Inc., (NASDAQ: VSTM) – May This Data Fuel Up Investor’s Confidence – Stock Watch (stocksnewstimes.com)
Verastem (NASDAQ:VSTM) opened at $2.92 on Tuesday. The company has a market cap of $124.91, a P/E ratio of -1.78 and a beta of 2.19. Verastem has a 12 month low of $1.11 and a 12 month high of $5.71. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.12 and a current ratio of 3.12.
Several research firms have recently weighed in on VSTM. Oppenheimer set a $13.00 target price on shares of Verastem and gave the stock a “buy” rating in a research note on Thursday, December 21st. HC Wainwright set a $10.00 target price on shares of Verastem and gave the stock a “buy” rating in a research note on Wednesday, December 13th. Raymond James Financial reiterated a “buy” rating on shares of Verastem in a research note on Monday, December 11th. Cantor Fitzgerald set a $17.00 target price on shares of Verastem and gave the stock a “buy” rating in a research note on Sunday, December 10th. Finally, Cann reiterated a “buy” rating and issued a $15.00 target price (up previously from $6.00) on shares of Verastem in a research note on Sunday, December 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $9.78.
In other news, Director Timothy J. Barberich acquired 60,538 shares of Verastem stock in a transaction that occurred on Tuesday, December 5th. The stock was bought at an average price of $3.95 per share, with a total value of $239,125.10. Following the completion of the purchase, the director now owns 130,000 shares in the company, valued at $513,500. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.51% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: “Verastem (VSTM) Receives Daily Media Sentiment Rating of 0.10” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.watchlistnews.com/verastem-vstm-receives-daily-media-sentiment-rating-of-0-10/1799554.html.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.